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ABSTRACT 
 
Oreocnide integrifolia (Gaud.)Miq (Urticaceae) leaves are used to alleviate diabetic symp-
toms in folk medicine in northeast India. In the present study, dose and duration dependent 
hypoglycemic potentials were evaluated in streptozotocin induced diabetic rats. Administra-
tion of aqueous leaf extract (100, 250, 500 and 750 mg/kg body weight orally once daily) to 
diabetic rats reduced glycemic levels by 56 % by 4 weeks of treatment and was comparable to 
standard reference drug Metformin. The experimental data also revealed significant improve-
ment in lowering lipid profile, Urea, Creatinine, Hb, HbA1c and insulin levels. The present 
study clearly demonstrates hypoglycemic and hypolipidemic potential of Oreocnide integrifo-
lia leaf extract. 
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INTRODUCTION 
Diabetes mellitus is characterized by an 
initial loss of glucose homeostasis resulting 
from defects in insulin secretion and/or in-
sulin action or leading to impaired metabo-
lism of glucose and other energy-yielding 
metabolites (Scheen, 1997). It is also ac-
companied by hyperglycaemia, dyslipidae-
mia, hypertension, decreased fibrinolytic 
activity, increased platelet aggregation, and 
severe atherosclerosis, all of which are po-
tential risk factors. 
Though several drugs targeting carbo-
hydrate hydrolyzing enzymes (pseudosac-
charides), release of insulin from pancreatic 
β-cells (sulphonylurea), glucose utilization 
(biguanides), insulin sensitization and 
PPARγ agonists (glitazones) are in clinical 
practice, there is a growing market for anti-
diabetic agents. Many of these oral antidia-
betic agents have been reported to show 
serious adverse effects (Zhang and Moller, 
2000). The multifactorial etiology and mul-
tiple pathogenic manifestation of diabetes 
demands multi-modal therapeutic approach 
and, future therapeutic strategies require 
evaluation of efficacy of combination of 
drugs. 
Management of diabetes sans side ef-
fects is still a challenge for the pharmaceu-
tical world. Traditional knowledge of me-
dicinal plants has become a recognized tool 
in research for the search of new sources of 
drugs and neutraceuticals (Sharma and Mu-
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jundar, 2003). In fact, metformin, one of the 
most prescribed glucose-lowering medi-
cines currently used, is derived from a 
chemical isolated from a plant (Witters, 
2001). 
The World Health Organization has in-
fact recommended the use of herbal medi-
cine especially in developing countries 
(WHO, 2002).Because of their perceived 
effectiveness, minimal side effects in clini-
cal experience and effectiveness, herbal 
drugs are prescribed widely even when their 
biologically active compounds are not 
known (Valiathian, 1998).  
The local communities residing in the 
biodiversity-rich areas of the north eastern 
region of India have traditionally used and 
relied on herbs for treating various ail-
ments. In many cases, local knowledge of 
medicinal plants remains poorly docu-
mented in scientific literature. These plants 
have found a prime place in the indigenous 
system of medicine and are in focus for 
evaluation of their active ingredients. 
Oreocnide integrifolia (Gaud.)Miq 
(family Urticaceae) are trees of 5-20 m 
height having reddish brown branchlets and 
simple, alternate, spiral and clustered leaves 
at twig end, found in wet evergreen forests 
at 300-1400 m height. They are mainly dis-
tributed in India, China, Bhutan, Indonesia, 
Laos, Myanmar, Sikkim and Thailand 
(Chen et al., 2003). The roots of Oreocnide 
integrifolia are mixed with ginger powder 
and applied for treatment of  rashes by 
Khasi and Jayantia tribes of Meghalaya 
(Begum and Nath, 2000; Kharkongor and 
Joseph, 1981). In north eastern states of In-
dia it is popularly known as ukhajing (ma-
nipuri), bonrhea (assamese), gingsining 
(garo) and dieng teingbah (khasi), and an 
infusion prepared from the leaves is used as 
a decoction to alleviate diabetic symptoms. 
Based on our literature survey till date, 
there are no scientific reports and hence the 
present study in this behest was undertaken 
to evaluate the hypoglycemic and hypolipi-
demic potential of Oreocnide integrifolia 
leaf extract on streptozotocin induced ex-
perimental diabetes. 
MATERIALS AND METHODS 
Plant material and extraction 
Fresh green leaves were collected dur-
ing the month of October from Imphal dis-
trict (Manipur) and authenticated by bota-
nist Dr. Hemchand Singh, D.M. College of 
Science, Manipur University. A voucher 
specimen (#344) of the herbarium has been 
deposited at the same department for future 
reference. The leaves were collected during 
the month of Sep-Oct, washed thoroughly 
and shade dried at room temperature. The 
dried leaves were subjected to size reduc-
tion to a coarse powder by using dry grind-
er and passed through (# 400) sieve. Two 
hundred grams of powder was mixed with 1 
litre of Milli Q water (Millipore, Billerica, 
MA) and boiled for 30 min and then left to 
cool down to room temperature. The decoc-
tion was filtered (Whatmann # 01) using a 
suction apparatus and the filtrate was ly-
ophilized and stored in a freezer at −20 °C. 
The extractive value of the aqueous extract 
in terms of yield was about 16.9 % (w/w). 
 
Experimental animals 
Female Charles foster rats (200–230 g) 
were housed in clean polypropylene cages 
under controlled room temperature 
(21 ± 2 ºC).They were fed with comercially 
available rat chow (M/s Pranav Agro Ltd., 
Baroda) and provided with water ad libi-
tum. The experiment was carried out ac-
cording to the guidelines of the Committee 
for the Purpose of Control and Supervision 
of Experiments on Animals (CPCSEA), In-
dia and approved by the Animal Ethical 
Committee of Department of Zoology, The 
M.S. University of Baroda, Vadodara (Ap-
proval No. 827/ac/04/ CPCSEA). 
 
Induction of Type I diabetes 
Rats were rendered diabetic by single 
intraperitoneal administration of strepto-
zotocin (60 mg/kg) dissolved in 0.1 M Cit-
rate buffer, pH 4.5. Seven days later, blood 
samples were collected and blood glucose 
levels determined to confirm induction of 
diabetes. Only those animals which showed 
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fasting blood glucose levels higher than 
250 mg/dl were used for the experiment. 
 
Experimental procedure 
Sixty-six rats (30 normal and 36 dia-
betic rats) were divided into eleven groups 
of six animals each. Group I consisted of 
normoglycemic rats (NC) administered 
with vehicle alone while, Groups II, III, IV, 
and V (NOI100, NOI250, NOI500, 
NOI750) consisted of normoglycemic rats 
treated 100, 250, 500 and 750 mg/kg body 
weight of OI (Oreocnide integrifolia) ex-
tract respectively. Group VI comprised of 
diabetic rats (DC) which received vehicle 
only while Groups VII, VIII, IX and X 
(DOI100, DOI250, DOI500 ,DOI750) con-
sisted of diabetic rats treated with 100, 250, 
500 and 750 mg/kg body weight of OI ex-
tract respectively. Group XI (DMet) con-
sisted of diabetic rats treated with met-
formin, an antidiabetic drug (50 mg/kg). All 
animals received their respective drugs in 
0.5 % Sodium carboxymethylcellulose 
orally via gastric intubation for a period of 
28 days. 
Biochemical determinations 
After overnight fasting, blood samples 
were collected by retro-orbital sinus punc-
ture from experimental animals on 0, 7th, 
14th, 21st and 28th day of experimentation 
(Table 1). Plasma was separated by cen-
trifugation at 3000 rpm for 10 min at 4 °C. 
Plasma glucose levels were estimated by an 
analytical Kit (Biogamma, Labkit, Italy). At 
the end of experimentation on 28th day, 
plasma high density lipoprotein (HDL), 
triglycerides (TG), total cholesterol (TC), 
phospholipids (PHL), creatinine, urea and 
haemoglobin (Hb) were estimated by spe-
cific analytical kits (Merck Diagnostics, 
Mumbai) while, glycosylated haemoglobin 
(HbA1c) was estimated by cation-exchange 
resin method kit (Monozyme Pvt. Ltd., 
Secunderabad, India). Plasma insulin levels 
were assayed using rat insulin ELISA kit 
(Mercodia Diagnostics, Sweden). Low den-
sity lipoprotein (LDL) and very low density 
lipoprotein (VLDL) were calculated by 
Friedwald’s formula (Friedwald et al., 
1972).  
 
 
 
Table 1: Effect of OI extract on fasting blood glucose levels at 0, 7th, 14th, 21st and 28th day of treat-
ment 
 
Group I was compared with Group II, III, IV and V 
Group VI was compared with Group VII, VIII, IX, X and XI 
where a =p<0.05, b=p< 0.01and c= p<0.001 
where * = mg/dl 
 
Blood Glucose* Groups Treatments 
0th Day 7th Day 14th Day 21st Day 28th Day 
I NC 105.4±11.74 102.3±  6.00 103.9±  9.70 97.25±12.05 104.9±  8.30 
II NC + O.I 100 102.9±  4.37 106.4±12.05   99.9±  3.70 109.5±15.15 98.25±11.95 
III NC + O.I 250 110.6±  9.34 107.5±11.15 104.1±  3.80 102.7±  6.40 110.3±  5.35 
IV NC + O.I 500 105.7±  9.30 106.6±15.95 106.7±  6.25 103.0±  6.05 110.6±  5.35 
V NC + O.I 750 106.1±  3.50 110.4±13.15 100.4±  7.20 111.6±  9.70 100.6±  4.70 
VI DC 432.4±23.26 456.2±27.05 412.8±16.15 423.1±13.15 429.3±23.10 
VII DC + O.I 100 427.7±16.51 415.8±13.85 400.8±13.65 381.2±19.00 367.4±17.20 
VIII DC + O.I 250 433.3±12.99 412.6±19.35 394.6±16.40 366.5±20.70 351.3±16.10 
IX DC + O.I 500 441.6±24.27 337.7±15.80a 289.6±13.65b 232.6±12.35c 207.2±10.85c 
X DC + O.I 750 439.4±16.30 316.8±12.20b 277.3±17.25c 236.2±15.90c 186.6±17.35c 
XI DC+ Metformin 427.6±20.75 318.7±12.45b 241.4±19.90c 186.5±15.85c 147.6±14.70c 
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Statistical analysis 
Statistical evaluation of the data was 
done by one way ANOVA followed by 
Bonferroni’s Multiple comparison test. The 
results are expressed as mean ± S.E.M us-
ing Graph Pad Prism version 3.0 for Win-
dows, Graph Pad Software, San Diego, 
CA/USA. 
 
RESULTS 
 
Plasma glucose 
DC group recorded significantly ele-
vated plasma blood glucose levels through-
out the study period (p<0.001). Administra-
tion of extract to diabetic rats showed sig-
nificant reduction in blood glucose levels. 
Low doses of extract (DOI100 and 
DOI250 mg/kg) had no significant effect on 
plasma blood glucose throughout study pe-
riod (Table 2). Higher doses of extract 
(DOI500 and DOI750 mg/kg) proved to be 
very potent as glycemic indices were sig-
nificantly reduced especially between 7th 
and 28th days of study.  
 
Plasma lipid profile 
Diabetic animals recorded significant 
increase in plasma TC (p<0.05), TG 
(p<0.05), FFA (p<0.05) and PHL (p<0.05), 
while HDL levels recorded a significant 
decrement (p<0.05). Low doses of extract 
(DOI100 and DOI250 mg/kg of body 
weight) did not have any significant effect 
in decreasing in plasma lipid profile, but 
higher doses of extract (DOI500 and 
DOI750 mg/kg of body weight) showed 
lowered plasma lipid profile significantly 
while increasing HDL levels (Table 3). 
These results were comparable with met-
formin treated diabetic rats. OI extract did 
not have any significant effect on plasma 
lipid profile in control rats (Table 3). 
 
Plasma Hb, urea, creatinine, HbA1c and 
insulin levels 
Diabetic rats recorded significant dec-
rement in haemoglobin content and increase 
in glycosylated haemoglobin along with 
increase in urea and creatinine levels. Low 
doses of extract (DOI100 and DOI250 
mg/kg of body weight) were not able to in-
duce significant changes in levels of hae-
moglobin and urea contents (Table 4) 
though, glycosylated haemoglobin recorded 
a significant decrement. 
 
Table 2: Effect of OI extract on plasma total cholesterol (TC), triglycerides (TG), free fatty acids (FFA) 
and phospholipids (PHL) levels after 28 days of treatment 
Group I was compared with Group II, III, IV and V 
Group VI was compared with Group VII, VIII, IX, X and XI 
where a =p<0.05, b=p< 0.01and c= p<0.001. 
where * = mg/dl 
Groups Treatments TC * TG * FFA * PHL * 
I NC 38.1±2.58 44.3±3.98 40.4±2.15 101.5±2.85 
II NC+ O.I 100 35.7±2.45  42.8±2.82  40.1±1.14  103.4±1.21  
III NC + O.I 250 41.7±3.45  48.2±2.90  42.9±1.62  99.83±3.50  
IV NC + O.I 500 40.5±2.20  42.0±3.68  43.0±2.00  100.5±3.51  
V NC + O.I 750 41.0±1.33  43.2±3.13  41.2±1.47  102.3±3.01  
VI DC 71.0±2.95 83.7±3.31  76.6±2.35 134.6±3.38 
VII DC + O.I 100 71.7±1.30  74.8±2.58  72.2±1.84  128.0±2.66  
VIII DC + O.I 250 66.8±1.85 67.2±2.11 67.9±1.49  120.0±1.36  
IX DC + O.I 500 54.2±1.83a 53.6±3.38a 51.2±1.18c 107.8±2.49b 
X DC + O.I 750 47.0±1.31b 43.5±1.52b 43.5±1.46c 99.35±3.01c 
XI DC+Metformin 47.3±1.97b 42.7±2.41b 44.9±1.00c 94.83±3.49c 
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Table 3: Effect of FEOI extract on plasma lipoproteins levels and atherogenic index after 28 days of 
treatment 
Plasma lipoprotein levels  Groups Treatments 
LDL-C* VLDL-C* HDL-C* 
Atherogenic index 
      
I NC 25.86±1.20   8.86±0.80 21.10±0.80  1.81 
II NC+ O.I 100 22.66±1.63    8.56±0.56  21.60±0.70  1.65 
III NC + O.I 250 31.24±1.59    9.64±0.58  20.10±1.20  2.07 
IV NC + O.I 500 26.99±1.96    8.40±0.74  21.95±0.35  1.85 
V NC + O.I 750 30.06±1.83    8.64±0.63  19.60±1.70  2.09 
VI DC 74.14±2.00 16.74±0.66 13.60±1.30 5.22 
VII DC + O.I 100 72.26±1.33  14.96±0.52  14.40±1.20  4.98 
VIII DC + O.I 250 64.99±2.01  13.44±0.42  15.25±1.05  4.38 
IX DC + O.I 500 45.52±1.45c 10.72±0.68b 20.40±1.10  2.66 
X DC + O.I 750 34.00±1.77c   8.70±0.31c 21.70±1.50a 2.17 
XI DC+Metformin 34.24±1.98c   8.54±0.48c 21.60±0.70a 2.19 
Group I was compared with Group II, III, IV and V 
Group VI was compared with Group VII, VIII, IX, X and XI 
where a =p<0.05, b=p< 0.01and c= p<0.001 
where * = mg/dl 
Table 4: Effect of OI extract on hemoglobin (Hb), glycosylated hemoglobin (HbA1c), insulin, urea and 
creatinine levels after 28 days of treatment 
Group I was compared with Group II, III, IV and V 
Group VI was compared with Group VII, VIII, IX, X and XI 
where a =p<0.05, b=p< 0.01and c= p<0.001 
where @ = g/dl, # = Hb%, $ = µIU/ml and * = mg/dl 
 
Groups Treatments Hb@ HbA1c# Insulin$ 
 
Urea* Creatinine* 
I 
II 
III 
IV 
V 
VI 
VII 
VIII 
IX 
X 
XI 
NC 
NC+ O.I 100 
NC + O.I250 
NC + O.I500 
NC + O.I750 
DC 
DC + O.I100 
DC + O.I250 
DC + O.I500 
DC + O.I750 
DC+Metformin
13.20±0.20  
13.50±0.20  
12.90±0.30  
13.20±0.20  
12.90±0.50  
  8.90±0.10 
  8.90±0.40  
  9.70±0.20  
  9.40±0.30  
10.30±0.20  
12.40±0.20c 
  6.40±0.20  
  6.40±0.10  
  6.60±0.10  
  6.20±0.10  
  6.40±0.20  
12.90±0.20 
10.35±0.25c 
  9.85±0.15c 
  8.60±0.30c 
  8.20±0.20 
  8.70±0.20c
25.61±0.21 
24.57±0.18 
24.81±0.61 
25.06±0.20 
24.28±0.13 
  6.18±0.21 
  8.08±0.24 
11.51±0.19 a 
14.16±0.27 b 
15.64±0.18 c 
18.64±0.30 c 
25.60±3.20  
24.80±2.10  
25.60±1.40  
25.25±1.95  
26.60±1.60  
43.20±2.10  
40.90±2.20  
33.70±3.10  
27.75±1.05b 
26.43±1.07b 
26.12±1.11b 
24.50±2.30  
26.25±1.05  
24.30±2.10  
23.70±2.20  
24.30±0.80 
46.20±3.40  
42.10±0.70  
32.46±2.10a 
27.85±1.51b 
29.81±1.44b 
34.34±1.01a
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Higher dose of extract (DOI500 and 
DOI750 mg/kg) registered a significant in-
crement in haemoglobin content with a 
concomitant decrement in glycosylated 
haemoglobin, urea and creatinine contents 
(p<0.05). These results were comparable to 
metformin treated rats. OI extract admini-
stration did not have any significant effect 
on any of the parameters. Grading of urine 
sugar level by Benedicts qualitative analy-
sis revealed very high sugar content in DC 
rats while it was in trace amounts in 
DOI750 rats. Insulin titre in the animals 
was significantly lower while there was 
significant improvement in DOI750 rats. 
The DCMet animals showed slightly more 
elevated level compared to DOI750 but still 
less than the control level (Table 4). 
 
DISCUSSION 
 
Chronic hyperglycemia associated with 
diabetes is known to induce glycation of 
body proteins which leads to secondary 
complications affecting eyes, kidneys, 
nerves and arteries (Sharma, 1993). Insulin-
dependent diabetes mellitus or type 1 diabetes 
is an autoimmune disorder caused by destruc-
tion of insulin producing β-cells when auto 
aggressive T-lymphocytes infiltrate the islets 
and leads to hypoinsulinaemia and thus hy-
perglycemia. 
Streptozotocin (STZ) has been proposed 
to act as a diabetogenic agent due to its 
ability to destroy pancreatic beta cells by 
the generation of excessive free radicals 
(Szkudelski, 2001). Streptozotocin enters 
the pancreatic β-cell via a glucose trans-
porter-GLUT2 and causes alkylation of 
DNA and impairment in glucose oxidation 
(Bolaffi et al., 1987) leading to decreased 
insulin biosynthesis and secretion (Naka-
tsuka et al., 1990). 
The present study using OI extract in 
type 1 diabetic rats has shown both dosage 
and duration dependent favorable effects. 
The attributed anti-hyperglycemic effects of 
most of the plants is due to their ability to 
restore islet function by causing an increase 
in insulin output or by inhibiting the intesti-
nal absorption of glucose or even by facili-
tation of metabolites in insulin dependent 
processes. Hence treatment with herbal 
drugs has an effect on protecting β-cells and 
smoothening out fluctuation in glucose lev-
els (Jia et al., 2003; Elder, 2004). The 
antidiabetic efficacy of OI extract is clearly 
indicated by the significant hypoglycemic 
effect following a 4 week treatment of dia-
betic rats. The OI extract clearly shows a 
duration as well as dose dependent effect. 
Both DOI100 and DOI250 mg of OI extract 
treatment had a similar duration dependent 
effect with 14-18 % decrease in glycemic 
levels at end of 28 days. Similarly, both 
DOI500 and DOI750 mg of OI extract 
treatment had similar duration dependent 
efficacy with a maximal 51-56 % decline in 
glycemic level by 28 days. The metformin 
treated diabetic rats at the same time 
showed a 65 % decrease in glycemic level. 
However, the absolute glycemic levels of 
DOI750 and DMet groups of rats are not 
statistically different. Apparently, though 
both DOI500 and DOI750 had similar dura-
tion dependent decline in glycemic level, 
the DOI750 effect at the end of 28 days 
seems to be relatively better and very much 
similar to the effects of the marketed anti-
diabetic drug. Apparently, the anti-
hyperglycemic effects of both DOI750 and 
DMet is to a greater extent accreditable to 
the improvement in insulin level brought 
about by these agents from the low level 
seen in DC rats. The lower insulin titre and 
marked hyperglycemia in DC rats is well 
reflected in the observed increase in HbA1c 
level and decrease in Hb content, quite sug-
gestive of glycosylation of proteins, a seri-
ous issue of diabetes that is responsible for 
many secondary complications. It is re-
markable that in this context, there is 100 % 
increase in HbA1c levels in DC rats and 
treatment with DOI750 reversed this sig-
nificantly to 30 % of control level very 
much similar to the result obtained by 
treatment with DMet. Clearly, the similarly 
degree of increase in peripheral insulin titre 
and hypoglycemia are responsible for the 
observed decrease in HbA1c and increase in 
haemoglobin in DOI750 and DMet treated 
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diabetic rats. Similar observations have 
been made even with other plant products 
(Bopanna et al., 1997; Venkateswaran and 
Pari, 2002). 
Insulin is a powerful metabolic hor-
mone singularly countering the lipolytic 
actions of all other hormones like gluca-
gons, catecholamines, growth hormone etc. 
Essentially, these hormones activate the 
hormone sensitive lipase in peripheral de-
pots (adipose tissue) bringing about lipoly-
sis contributing to hyperlipidemia and hy-
percholesterolemia as well as increased 
loads of hepatic and renal lipids and choles-
terol. Insulin deficiency, as it occurs during 
diabetes, favours the actions of hormone 
sensitive lipase and increases secondary 
risk factors in the form of increased plasma 
lipid fractions. This is clearly validated by 
the herein, observed significant (2-3 folds) 
increase in various plasma lipid fractions in 
STZ induced DC rats. Similar observations 
are recorded in literature in the many stud-
ies on induced diabetes (Gupta et al., 2009; 
Rajkumar et al., 2005). OI extract treatment 
is found to be effective in lowering the DC 
specific plasma lipid parameters with 
DOI750 being the most potent almost nor-
malizing all the lipid values very much 
similar to the response obtained with Met-
formin. The OI extract effectively lowered 
cholesterol, triglyceride and LDL-C levels 
and increased HDL-C levels. There are 
similar reports on the ability of other me-
dicinal plants also exhibiting potential 
hypolipidemic and hypocholesterolemic 
effects (Pari and Latha, 2002; Mitra et al., 
1995). The underlying mechanism of lipid 
lowering activity of OI extract may be cor-
related with this ability to increase insulin 
level and the consequent mechanism of ac-
tion as suggested above. Since, diabetes in-
duced hyperlipidaemia is attributable to ex-
cess mobilization of fats from adipose tis-
sue, due to under utilization of glucose 
(Khanna et al., 2002), the regression of dia-
betic state on OI extract administration in-
ferably increases utilization of glucose by 
the recovered insulin levels, thereby de-
pressing the mobilization of fat. The hypo-
cholesterolemic action of OI extract can be 
associated with a decrease in LDL fraction 
as cholesterol lowering property can result 
from rapid catabolism of LDL-C through its 
hepatic receptor for final elimination in 
form of bile acids (Krishnakumar et al., 
2000). 
Postprandial elevation of triglyceride 
(TG)-rich lipoproteins (TRLs) is also a 
well-recognized feature of diabetic dyslipi-
demia and includes the accumulation of in-
testinally derived apolipoprotein B48 
(apoB48)-containing lipoproteins (Lewis et 
al., 1991; Curtin et al., 1996; Mero et al., 
1998). VLDL is normally converted to LDL 
via the actions of post-heparin lipases. The 
result from the present study suggests that 
the OI extract is able to restore, at least par-
tially, catabolism of β-lipoproteins and also 
as hypothesized by many works with other 
plants (Campillo et al., 1994; Pérez et al., 
1999). The restoration of catabolic metabo-
lism of VLDL could be due to an increased 
stimulation of the lipolytic activity of 
plasma lipoprotein lipase. 
The renoprotective effect of OI extract 
is also very clearly indicated by signifi-
cantly lowered plasma levels of creatinine 
and urea produced in higher amounts in DC 
rats. Apparently, OI extract has potent abil-
ity to afford protection against renal dam-
age generated in higher amounts under un-
controlled diabetes mellitus (Almdal and 
Vilstrup, 1988; Hwang et al., 1997). 
Several phytomolecules including fla-
vonoids, alkaloids, glycosides, saponins, 
glycolipids, dietary fibres, polysaccharides, 
peptidoglycans, carbohydrates, amino acids 
and others obtained from various plant 
sources have been reported as potent hypo-
glycemic agent (Mukherjee et al., 2006). 
Flavonoids are a heterogeneous group of 
ubiquitous plant polyphenols, that exhibits 
a variety of pharmacological activities, in-
cluding the anti-atherogenesis effect, lipo-
protein oxidation, blood platelet aggrega-
tion and vascular reactivity (Del Bas et al., 
2005; Peluso, 2006). Triterpenoid and ster-
oidal glycosides, referred to collectively as 
saponins, are bioactive compounds present 
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naturally in many plants and known to pos-
sess potent hypoglycemic activity (Rao and 
Gurfinkel, 2000). Qualitative phytochemi-
cal analysis of OI extract from our lab re-
vealed presence of flavanoids, phenolics, 
saponins, terpenoids, sugars and steroids 
(Ansarullah; personal communication). 
Hence, the observed antidiabetogenic ef-
fects of OI extract principally at the level of 
carbohydrate metabolism as well as secon-
dary on lipid metabolism could be accred-
ited to the many active compounds present 
in the extract. 
 
CONCLUSION 
 
Overall, it may be concluded that OI ex-
tract possesses hypoglycemic and hypo-
lipidemic potential and has been shown to 
afford significant protection against strepto-
zotocin diabetes. Currently, we are employ-
ing activity directed fractionation assays to 
further isolate and characterize the bioac-
tive compounds responsible for antidiabetic 
activity. 
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